AJArmindo Jreige Jr.

Armindo Jreige Jr.

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Armindo Jreige Jr. has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sacubitril/Valsartana versus Enalapril ou Losartana em Doses Máximas na Insuficiência Cardíaca com Fração de Ejeção Reduzida: Dados de Mundo Real

    by Renato de Carvalho Barros, Vinícius C. Fiusa, Gabrielle N. Tim, Victoria T. V. Goulart, Caio Henrique M. Nascimento, Gustavo T. de Moura, Adriana J. B. A. Guimarães, Sergio Henrique Rodolpho Ramalho, Armindo Jreige Jr., Filipe A. Moura, et al.

    Resumo Fundamento: Sacubitril/valsartana reduziu a mortalidade e as hospitalizações em pacientes com insuficiência cardíaca com fração de ejeção reduzida (ICFEr) em comparação com enalapril em estudos clínicos pivotais. No entanto, os dados de mundo real sob doses otimizadas continuam limitados. Objetivo: Comparar os desfechos de pacientes com ICFEr tratados com sacubitril/valsartana versus enalapril ou losartana nas doses máximas recomendadas pelas diretrizes. Métodos: Analisamos dados de uma coorte observacional de insuficiência cardíaca (n = 2.314), incluindo pacientes atendidos entre agosto de 2010 e setembro de 2024 em seis hospitais públicos de uma grande área metropolitana. A análise primária incluiu 254 pacientes com ICFEr que receberam as doses máximas recomendadas pelas diretrizes dos medicamentos investigados. Uma análise de sensibilidade incluiu 452 pacientes que receberam quaisquer doses submáximas. O desfecho primário foi a combinação de hospitalização ou óbito. As diferenças basais foram ajustadas por meio do pareamento por escore de propensão. Foram considerados significativos valores de p < 0,05. Resultados: Entre 254 pacientes com ICFEr (idade média de 63,6 ± 12,3 anos, 61,4% do sexo masculino), 115 receberam sacubitril/valsartana 97/103 mg duas vezes ao dia, 33 enalapril 20 mg duas vezes ao dia e 106 losartana 100 mg ao dia. Durante um seguimento mediano de 23,9 meses (intervalo interquartil 11,9–41,1), ocorreram 70 eventos do desfecho primário (56 primeiras hospitalizações e 32 óbitos). Em comparação com doses equivalentes de enalapril ou losartana, sacubitril/valsartana não foi associado a reduções significativas na combinação de hospitalização ou mortalidade (odds ratio 0,650, intervalo de confiança de 95% 0,354–1,195, p = 0,165), mas foi associado à melhora do estado funcional (odds ratio 3,902, intervalo de confiança de 95% 1,745–8,726, p = 0,001). Conclusão: O presente estudo de mundo real não demonstrou reduções significativas de hospitalização ou mortalidade com sacubitril/valsartana em comparação a enalapril ou losartana nas doses máximas recomendadas pelas diretrizes; no entanto, sacubitril/valsartana foi associado à melhora da classe funcional.


  • Open Access

    Sacubitril/Valsartan versus Enalapril or Losartan at Maximum Doses in Heart Failure with Reduced Ejection Fraction: Real-World Data

    by Renato de Carvalho Barros, Vinícius C. Fiusa, Gabrielle N. Tim, Victoria T. V. Goulart, Caio Henrique M. Nascimento, Gustavo T. de Moura, Adriana J. B. A. Guimarães, Sergio Henrique Rodolpho Ramalho, Armindo Jreige Jr., Filipe A. Moura, et al.

    Background: Sacubitril/valsartan reduced mortality and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril in pivotal clinical trials. However, real-world data under optimized dosing remain limited. Objective: To compare the outcomes of HFrEF patients treated with sacubitril/valsartan versus either enalapril or losartan at guideline-recommended maximum dosages. Methods: We analyzed data from an observational heart failure cohort (n = 2,314) including patients receiving care between August 2010 and September 2024 at six public hospitals in a large metropolitan area. The primary analysis included 254 HFrEF patients receiving the guideline-recommended maximum dosages of the investigated drugs. A sensitivity analysis included 452 patients receiving any submaximal dosages. The primary outcome was combined hospitalization or death. Baseline differences were adjusted using propensity score matching. A p-value < 0.05 was considered significant. Results: Among 254 HFrEF patients (mean age 63.6 ± 12.3 years, 61.4% male), 115 received sacubitril/valsartan 97/103mg twice daily, 33 enalapril 20 mg twice daily, and 106 losartan 100 mg daily. Over the median follow-up of 23.9 months (interquartile range 11.9–41.1), there were 70 primary endpoint events (56 first hospitalizations, 32 deaths). Compared to equivalent dosages of enalapril or losartan, sacubitril/valsartan was not associated with significant reductions in combined hospitalization or death (odds ratio 0.650, 95% confidence interval 0.354–1.195, p = 0.165), but it was associated with functional status improvement (odds ratio 3.902, 95% confidence interval 1.745–8.726, p = 0.001). Conclusion: This real-world study did not demonstrate significant reductions in hospitalization or mortality for sacubitril/valsartan compared with enalapril or losartan at guideline-recommended maximum dosages; however, sacubitril/valsartan was associated with improved functional status.

  • Open Access

    Determinants of Aortic Prosthesis Mismatch in a Brazilian Public Health System Hospital: Big Patients or Small Prosthesis?

    by Maria Estefania Otto, Fernando Antibas Atik, Marcelo do Nascimento Moreira, Luiz Carlos Madruga Ribeiro, Bianca Correa Rocha de Mello, Joyce Gomes Elias Lima, Maiara Sanchez Ribeiro, Ana Carolina Pereira Matos Domingues, Reyna Pinheiro Calzada, Armindo Jreige Jr, et al.

    Background: Prosthesis-patient mismatch (PPM) is associated with worse outcomes. Objective: Determine the frequency and evaluate preoperatory variables independently associated with severe PPM in a tertiary hospital focused on Public Health Care. Methods: A total of 316 patients submitted to aortic valve replacement, who had echocardiography performed within the first 30 days after surgery, were retrospectively analyzed. The indexed effective orifice area (iEOA) of the prosthesis was used to classify the patients into three groups, according to PPM, considering body mass index (BMI): severe PPM (iEOA) < 0.65 cm(2)/m(2)), mild to moderate PPM (iEOA, 0.65 cm(2)/m(2) - 0.85 cm(2)/m(2)) and without PPM (iEOA > 0.85 cm(2)/m(2)) for a BMI < 30 kg/m(2) and severe PPM (iEOA) < 0.55 cm(2)/m(2)), mild to moderate (iEOA, 0.55 cm(2)/m(2) - 0.70 cm(2)/m(2)) and without PPM (iEOA > 0.7 cm(2)/m(2)) for a BMI > 30 kg/m(2). Statistical significance was considered when p < 0.05. Results: iEOA was obtained in 176 patients. The frequency of severe and moderate PPM was 33.4% and 36.2%, respectively. Severe PPM patients were younger and had larger BMI, but smaller left ventricular outflow tract diameter (LVOTD). The independent variables used to predict severe PPM were male gender, BMI > 25 kg/m(2), age < 60 years, LVOTD < 21 mm, and rheumatic etiology with an area under the ROC curve of 0.82. Conclusion: The frequency of severe PPM is high in a Brazilian population representative of the Public Health System, and it is possible to predict PPM from preoperative variables such as rheumatic valvular disease, gender, BMI, age and LVOTD.